Merck Halts Second PAH Drug Study Early on Strong Efficacy Results
MRK's decision to stop the late-stage HYPERION study on PAH drug Winrevair ahead of time comes after evaluating the drug's ...
Merck to stop lung condition drug study early due to strong efficacy data
Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on ...
Nasdaq7d
Merck Halts Second PAH Drug Study Early on Strong Efficacy Results
Merck MRK has decided to stop the phase III HYPERION study early. The study evaluates MRK’s pulmonary arterial hypertension (PAH) drug, Winrevair (sotatercept), for a more advanced version of ...
FiercePharma8d
With efficacy assured, Merck halts another trial of blockbuster-to-be Winrevair
All patients in the trial will have the opportunity to resume or begin treatment with Winrevair, the company said.
FiercePharma3d
Merck halts Gardasil shipments to China, withdraws $11B sales target as demand nosedives
The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is ...
Merck's SWOT analysis: pharma giant's stock faces China setback, PAH potential
Co., Inc. (NYSE:MRK), a global healthcare leader, finds itself at a crossroads as it navigates challenges in its China Gardasil business while capitalizing on opportunities in pulmonary arterial ...